MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MediciNova completed the last patient, last visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast), which randomized 234 ALS patients across U.S. and Canadian sites. The company expects topline results by the end of 2026, while the full study including its open-label extension is expected to reach last patient, last visit in March 2027. The milestone reduces trial-execution risk but does not provide efficacy or safety results.

Analysis

MNOV has transitioned from enrollment/execution risk to a binary efficacy-and-safety readout risk. The key near-term valuation driver is not the extension study, but whether the double-blind dataset shows a clinically credible slowing of ALS functional decline with a safety profile that supports chronic use; a statistically marginal result is unlikely to command a durable rerating absent a clear regulatory path. With only one disclosed near-term catalyst and limited ability for investors to independently infer efficacy from the release, any pre-results rally is likely to be liquidity- and positioning-driven rather than fundamentally underwritten.

Over the next 1-3 months, investor attention should shift to cash runway, trial discontinuation rates, baseline balance between arms, and whether management provides a specific topline date. These details determine financing overhang: a weak balance sheet into a late-stage readout can cap upside because success may still require a discounted equity raise to fund regulatory work and commercialization. A positive signal could also create strategic value for larger neurodegeneration franchises, but ALS commercialization economics remain constrained by a small patient population and payer scrutiny unless functional benefit is unambiguous.

Contrarian view: the completion milestone alone has little informational value on probability of success; completion can be associated with both clean execution and fully accrued negative outcomes. The asymmetry may nevertheless favor a tightly sized event position if MNOV's enterprise value remains below a conservative probability-weighted value of an approvable ALS asset, but that requires verification of net cash, share count, and prior MN-166 efficacy evidence. Falsification for a bullish setup is evidence of excess discontinuations, a material cash shortfall before data, or a topline delay beyond year-end.

Key Decisions for Investors

• Do not chase MNOV on the operational milestone; place it on an event-driven watchlist pending confirmation of cash runway, fully diluted shares, and a firm topline date. Reassess 4-8 weeks before results, when implied event risk can be compared with probability-weighted upside.
• For a high-risk biotech sleeve only, consider a small long MNOV position 1-2 months ahead of topline if enterprise value is still substantially supported by net cash and there is no financing need before the readout; size for a potential 50%+ loss on negative or equivocal data.
• Avoid shorting MNOV outright into the data catalyst: low-float biotech mechanics and takeout optionality can create disproportionate upside. A bearish view is better expressed by avoiding participation or using defined-risk put structures only if listed options offer reasonable implied volatility.
• Set diligence alerts for: year-end results timing, cash-burn guidance, discontinuation/safety commentary, and any capital raise. A raise before data or a delay past December would materially weaken the risk/reward and invalidate a pre-catalyst long.